Dec 31, 2021

CVS Health Q4 2021 Earnings Report

Reported strong Q4 and full-year results, confirming full-year EPS guidance for 2022.

Key Takeaways

CVS Health's Q4 2021 total revenues increased to $76.6 billion, up 10.1% compared to the prior year. GAAP diluted EPS was $0.98, and adjusted EPS was $1.98. The company administered over 8 million COVID-19 tests and 20 million vaccines in Q4 2021.

Total revenues increased to $76.6 billion, up 10.1% compared to prior year.

GAAP diluted EPS from continuing operations was $0.98, and Adjusted EPS was $1.98.

The company administered more than 8 million COVID-19 tests and more than 20 million COVID-19 vaccines nationwide.

CVS Health unveiled several steps to support the acceleration of the Company’s omnichannel health strategy.

Total Revenue
$76.6B
Previous year: $69.6B
+10.1%
EPS
$1.98
Previous year: $1.3
+52.3%
Gross Profit
$13.7B
Previous year: $12B
+14.2%
Cash and Equivalents
$9.41B
Previous year: $7.85B
+19.8%
Free Cash Flow
$3.41B
Previous year: $2.85B
+19.4%
Total Assets
$233B
Previous year: $231B
+1.0%

CVS Health

CVS Health

CVS Health Revenue by Segment

Forward Guidance

The Company confirmed its full-year 2022 GAAP diluted EPS from continuing operations guidance range of $7.04 to $7.24 and its full-year 2022 Adjusted EPS guidance range of $8.10 to $8.30. The Company also revised its full-year 2022 cash flow from operations guidance range to $12.0 billion to $13.0 billion from $12.5 billion to $13.0 billion.

Revenue & Expenses

Visualization of income flow from segment revenue to net income